RE:RE:RE:How long ?I agree that their website states 46.2%, but the NR states over 40% once the deal is complete. It accounts for some dilution, I suppose. Shenzhen Hepalink's ownership of 25 Mil shares in QPT makes them a majority shareholder.
"Immediately prior to execution of the definitive agreement, Quest was a 36% shareholder in OncoQuest. As part of the asset transfer agreement, Dual has committed to returning its 2.5 million OncoQuest shares. As a result, Quest’s ownership interest in OncoQuest will increase to over 40%."
It appears (as I understand it) that the entire OncoQuest drug portfolio will be transferred to Dual's US subsidiary once set up.
"Once all necessary transfers and releases have been obtained by OncoQuest, there will be a Second Closing, confirming transfer of all legal title and registrations for OncoQuest’s drug portfolio to Dual."
OncoQuest ends up with the US $125 in a perpetual convertible bond. Interest rate, not stated. And the US $175 Mil worth of Dual Common Stock. Dual trades at $2.94 US presently ($4.14 CAN). That equates to ~60 Mil Dual shares.
The bottom line here is that the deal overall is a good one for Quest Shareholders seeing that the ~40% ownership in OncoQuest is now well funded. Dual should be able to take OncoQuest immunotherapy development they started over the finish line.
This deal should move the SPP for "QPT". By how much,,,we'll see???
glta
G1945V